This article is a correction to:
Efficacy and safety of Janus kinase inhibitors in non-infectious inflammatory ocular diseases: a prospective cohort study from the international AIDA network registries
Antonio Vitale1,2†
Judith Palacios-Olid3†Valeria Caggiano1,2
Gaafar Ragab4,5
José Hernández-Rodríguez6
Laura Pelegrín6
Germán Mejía-Salgado7Laura Zarate-Pinzón7Stefano Gentileschi1,2
Jurgen Sota1,2
Alex Fonollosa8
Ester Carreño9,10
Carla Gaggiano1,2
Rana Hussein Amin11Alberto Balistreri2,12
Javier Narváez3
Gian Marco Tosi13Bruno Frediani1,2
Luca Cantarini1,2*
Alejandra de-la-Torre7
Claudia Fabiani2,13*- 1Department of Medical Sciences, Surgery and Neurosciences, Research Center of Systemic Autoinflammatory Diseases and Behçet's Disease Clinic, University of Siena, Siena, Italy
- 2Azienda Ospedaliero-Universitaria Senese [European Reference Network for Rare Immunodeficiency, Autoinflammatory and Autoimmune Diseases (RITA) Center], Siena, Italy
- 3Rheumatology Department, Hospital de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain
- 4Rheumatology and Clinical Immunology Unit, Internal Medicine Department, Faculty of Medicine, Cairo University, Giza, Egypt
- 5Faculty of Medicine, Newgiza University, 6th of October City, Egypt
- 6Department of Autoimmune Diseases, Institut d'Investigacions Biomèdiques August Pi I Sunyer, Hospital Clínic of Barcelona [European Reference Network for Rare Immunodeficiency, Autoinflammatory and Autoimmune Diseases (RITA) Center], University of Barcelona, Barcelona, Spain
- 7Neuroscience Research Group (NEUROS), NeuroVitae Center, Escuela de Medicina y Ciencias de la Salud, Universidad del Rosario, Bogotá, Colombia
- 8Department of Ophthalmology, Biocruces Bizkaia Health Research Institute, Cruces University Hospital, University of the Basque Country, Barakaldo, Spain
- 9Department of Ophthalmology, Hospital Universitario Rey Juan Carlos, Madrid, Spain
- 10Department of Ophthalmology, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
- 11Department of Ophthalmology, Cairo University, Giza, Egypt
- 12Bioengineering and Biomedical Data Science Lab, Department of Medical Biotechnologies, University of Siena, Siena, Italy
- 13Ophthalmology Unit, Department of Medicine, Surgery and Neurosciences, University of Siena, Siena, Italy
by Vitale, A., Palacios-Olid, J., Caggiano, V., Ragab, G., Hernández-Rodríguez, J., Pelegrín, L., Mejía-Salgado, G., Zarate-Pinzón, L., Gentileschi, S., Sota, J., Fonollosa, A., Carreño, E., Gaggiano, C., Amin, R. H., Balistreri, A., Narváez, J., Tosi, G. M., Frediani, B., Cantarini, L., de-la-Torre, A., and Fabiani, C. (2024). Front. Med. 11:1439338. doi: 10.3389/fmed.2024.1439338
In the published article, there was an error in Figure 1 as published. In the Figure 1 there are several errors in the panels, which are crucial for the selection of patients included in the study. “Uveitis registry” was changed to “AIDA registry”; “Behçet's disease” was removed from the middle right hand side panel; “Behçet's disease patients with ocular involvement treated with JAK inhibitors” was changed to “Patients treated with JAK inhibitors” in the bottom right hand side panel. The corrected Figure 1 and its caption appear below.
Figure 1
Figure 1. Flow-chart explaining the selection of patients included in this study starting from the total number of patients included in the AutoInflammatory Disease Alliance (AIDA) Network project.
In the published article, there was an error in Table 1 as published. In Table 1, there is a typographical error in the second to last row, “Extra ocular” was changed to “Extraocular”. The corrected Table 1 and its caption appear below.
Table 1
Table 1. Demographic, clinical and therapeutic features describing the twelve patients enrolled.
In the published article, there was an error. There are four sentences in which there are either structural or typographical errors.
A correction has been made to Patients and methods, Paragraph 1. This sentence previously stated:
“international AutoInflammatory Disease Alliance (AIDA) Network registries dedicated to uveitis, scleritis and Behçet's disease”.
The corrected sentence appears below:
“International AutoInflammatory Disease Alliance (AIDA) Network registries dedicated to uveitis, scleritis and Behçet's syndrome”.
A correction has been made to Results, Paragraph 1. This sentence previously stated:
“and one from the International AIDA Network registry dedicated to Behçet's disease (10)”.
The corrected sentence appears below:
“and one from the International AIDA Network registry dedicated to Behçet's syndrome (10)”.
A correction has been made to Treatment details, Paragraph 8. This sentence previously stated:
“Four patients were receiving combination therapy with cDMARDs at the start of treatment with JAK inhibitors: two were on azathioprine, and one on sulfasalazine. The follow-up period while on combination therapy was three months and eleven months for the patients on azathioprine, and seven months for the patient treated with sulfasalazine”.
The corrected sentence appears below:
“Four patients were receiving combination therapy with cDMARDs at the start of treatment with JAK inhibitors: two were on azathioprine, one was on leflunomide, and one was on sulfasalazine. The follow-up period while on combination therapy was three months and eleven months for the patients on azathioprine, seven months for the patient in therapy with sulfasalazine, and six months for the patient treated with leflunomide”.
A correction has been made to Discussion, Paragraph 6. This sentence previously stated:
“The lack of Gas withdrawal in these two cases was either due to systemic disease activity or the short follow-up duration”.
The corrected sentence appears below:
“The lack of GCs withdrawal in these two cases was either due to systemic disease activity or the short follow-up duration”.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: baricitinib, scleritis, tofacitinib, upadacitinib, uveitis
Citation: Vitale A, Palacios-Olid J, Caggiano V, Ragab G, Hernández-Rodríguez J, Pelegrín L, Mejía-Salgado G, Zarate-Pinzón L, Gentileschi S, Sota J, Fonollosa A, Carreño E, Gaggiano C, Amin RH, Balistreri A, Narváez J, Tosi GM, Frediani B, Cantarini L, de-la-Torre A and Fabiani C (2024) Corrigendum: Efficacy and safety of Janus kinase inhibitors in non-infectious inflammatory ocular diseases: a prospective cohort study from the international AIDA network registries. Front. Med. 11:1489092. doi: 10.3389/fmed.2024.1489092
Received: 31 August 2024; Accepted: 02 September 2024;
Published: 13 September 2024.
Edited and reviewed by: George E. Fragoulis, Laiko General Hospital of Athens, Greece
Copyright © 2024 Vitale, Palacios-Olid, Caggiano, Ragab, Hernández-Rodríguez, Pelegrín, Mejía-Salgado, Zarate-Pinzón, Gentileschi, Sota, Fonollosa, Carreño, Gaggiano, Amin, Balistreri, Narváez, Tosi, Frediani, Cantarini, de-la-Torre and Fabiani. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Luca Cantarini, cantariniluca@hotmail.com; Claudia Fabiani, claudia.fabiani@aidanetwork.org
†These authors have contributed equally to this work